
|Videos|August 26, 2021
Part 2: Practical Considerations For Venetoclax in AML
Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Current Pneumococcal Vaccination Recommendations: A Clinical Update
2
What Pharmacists Should Know About Most Favored Nation as Drug Prices Continue to Rise
3
Positive Phase 2a Trial Data Support FDA Clearance of StemCyte’s HPC Therapy for Long COVID
4
A Defining Moment for Health System Pharmacy: Advancing Competency, Policy, and Patient Need in 2026
5


























